Details of the SBP
| General Information of Synthetic Binding Protein (SBP) (ID: SBP000298) | ||||||
|---|---|---|---|---|---|---|
| SBP Name |
Macrocyclic peptide anti-C5 RA-101348
|
|||||
| Synonyms |
Macrocyclic peptide RA-101348
|
|||||
| Design Method | Traditional methods (Site-directed mutagenesis and/or Directed evolution) | |||||
| Highest Status | Research | |||||
| Protein Scaffold Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| Scaffold ID | PS044 | [1] | ||||
| Scaffold Name | Macrocyclic peptide | |||||
| Scaffold Class | Non-Antibody | |||||
| Fold Type | Beta-Sheets + Loops | |||||
| Binding Target(s) of This SBP (BTS) |
|---|
| BTS Name | Details | Mechanism | Application | Affinity | Research Organization | Ref |
|---|---|---|---|---|---|---|
| Complement C5 | Inhibitor | Haemolytic uraemic syndrome [ICD-11: 3A21.2]; Lupus nephritis [ICD-11: 4A40.0Y]; Motor neurone disease [ICD-11: 8B60.Z]; Myasthenia gravis [ICD-11: 8C60.Z]; Cardiomyopathy [ICD-11: BC43]; Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0]; Renal failure [ICD-11: GB6Z] | N.A. | Ra Pharmaceuticals | [1] | |